Contemporary management of peripheral arterial disease: III. Endovascular and surgical management

Article Type
Article
Changed
Tue, 09/25/2018 - 14:24
Display Headline
Contemporary management of peripheral arterial disease: III. Endovascular and surgical management
Author(s)
Amjad AlMahameed, MD, MPH, FACP
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Article PDF
content_73_Suppl_4_SI-45.pdf
Author and Disclosure Information

Amjad AlMahameed, MD, MPH, FACP
Division of Cardiology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA

Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Correspondence: Amjad AlMahameed, MD, Division of Cardiology, Beth Israel Deaconess Medical Center, Cardiology-W/Baker 4, One Deaconess Road, Boston, MA 02215; [email protected]

Dr. AlMahameed reported that he has received honoraria for teaching and speaking from Sanofi-Aventis, GlaxoSmithKline, and Pfizer.

Dr. Bhatt reported that he has received honoraria for teaching, speaking, and consulting from Sanofi-Aventis and from Bristol-Myers Squibb.

At the time this article was written, Dr. AlMahameed was on the staff of the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

Publications
Cleveland Clinic Journal of Medicine
Page Number
S45-S51
Author(s)
Amjad AlMahameed, MD, MPH, FACP
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Author(s)
Amjad AlMahameed, MD, MPH, FACP
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Author and Disclosure Information

Amjad AlMahameed, MD, MPH, FACP
Division of Cardiology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA

Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Correspondence: Amjad AlMahameed, MD, Division of Cardiology, Beth Israel Deaconess Medical Center, Cardiology-W/Baker 4, One Deaconess Road, Boston, MA 02215; [email protected]

Dr. AlMahameed reported that he has received honoraria for teaching and speaking from Sanofi-Aventis, GlaxoSmithKline, and Pfizer.

Dr. Bhatt reported that he has received honoraria for teaching, speaking, and consulting from Sanofi-Aventis and from Bristol-Myers Squibb.

At the time this article was written, Dr. AlMahameed was on the staff of the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

Author and Disclosure Information

Amjad AlMahameed, MD, MPH, FACP
Division of Cardiology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA

Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Correspondence: Amjad AlMahameed, MD, Division of Cardiology, Beth Israel Deaconess Medical Center, Cardiology-W/Baker 4, One Deaconess Road, Boston, MA 02215; [email protected]

Dr. AlMahameed reported that he has received honoraria for teaching and speaking from Sanofi-Aventis, GlaxoSmithKline, and Pfizer.

Dr. Bhatt reported that he has received honoraria for teaching, speaking, and consulting from Sanofi-Aventis and from Bristol-Myers Squibb.

At the time this article was written, Dr. AlMahameed was on the staff of the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

Article PDF
content_73_Suppl_4_SI-45.pdf
Article PDF
content_73_Suppl_4_SI-45.pdf
Page Number
S45-S51
Page Number
S45-S51
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Article Type
Article
Display Headline
Contemporary management of peripheral arterial disease: III. Endovascular and surgical management
Display Headline
Contemporary management of peripheral arterial disease: III. Endovascular and surgical management
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Using clopidogrel in acute coronary syndromes without ST-segment elevation

Article Type
Article
Changed
Mon, 12/17/2018 - 12:32
Display Headline
Using clopidogrel in acute coronary syndromes without ST-segment elevation
The CURE trial
Author(s)
Gregory P. Gerschutz, MD
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Article PDF
content_69_377.pdf
Author and Disclosure Information

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Issue
Cleveland Clinic Journal of Medicine - 69(5)
Publications
Cleveland Clinic Journal of Medicine
Topics
Cardiology
Drug Therapy
Page Number
377-378, 380, 382, 384-385
Sections
Interpreting Key Trials
Author(s)
Gregory P. Gerschutz, MD
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Author(s)
Gregory P. Gerschutz, MD
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Author and Disclosure Information

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Author and Disclosure Information

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Article PDF
content_69_377.pdf
Article PDF
content_69_377.pdf
The CURE trial
The CURE trial
Issue
Cleveland Clinic Journal of Medicine - 69(5)
Issue
Cleveland Clinic Journal of Medicine - 69(5)
Page Number
377-378, 380, 382, 384-385
Page Number
377-378, 380, 382, 384-385
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Topics
Cardiology
Drug Therapy
Article Type
Article
Display Headline
Using clopidogrel in acute coronary syndromes without ST-segment elevation
Display Headline
Using clopidogrel in acute coronary syndromes without ST-segment elevation
Sections
Interpreting Key Trials
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media
Subscribe to Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP